- Home
- FRSH vs ELVN Comparison
FRSH vs ELVN Comparison
Compare FRSH & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRSH | ELVN |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRSH | ELVN |
|---|---|---|
| Price | $12.04 | $51.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | $16.62 | ★ $74.33 |
| AVG Volume (30 Days) | ★ 5.0M | 1.6M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 296.88 | 3.17 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $838,809,000.00 | N/A |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | $13.96 | N/A |
| P/E Ratio | $203.75 | ★ N/A |
| Revenue Growth | ★ 16.43 | N/A |
| 52 Week Low | $6.79 | $14.79 |
| 52 Week High | $15.51 | $62.32 |
Technical Indicators
Market Signals| Indicator | FRSH | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 31.67 | 67.70 |
| Support Level | $11.83 | $37.77 |
| Resistance Level | $12.20 | $52.39 |
| Average True Range (ATR) | 0.63 | 2.14 |
| MACD | -0.40 | 1.24 |
| Stochastic Oscillator | 3.61 | 99.26 |
Price Performance
Historical ComparisonAbout FRSH Freshworks Inc.
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.